SOURCE: Nuvilex, Inc.

Nuvilex, Inc.

May 29, 2013 08:30 ET

Nuvilex, Inc.'s Medical Marijuana Research May Enhance Its Diabetes Studies

NEW YORK, NY--(Marketwired - May 29, 2013) - Nuvilex, Inc. (OTCQB: NVLX) and its medical marijuana subsidiary, Medical Marijuana Sciences, Inc., may have just found a way to work side by side in an area of study where the parent company is already engaged. Nuvilex, an international biotechnology firm, has conducted a preclinical diabetes study where the company was able to use its cell encapsulation technology to essentially develop a type of "artificial pancreas" that controls blood sugar levels and eliminates the need for insulin treatment.

Now, a newly published study could have the two companies working hand in hand studying the potential effects of cannabis use and its ability to lower blood sugar levels. The study published in the American Journal of Medicine may very well blend the two areas of research for Nuvilex.

In the study titled, "The Impact of Marijuana Use on Glucose, Insulin, and Insulin Resistance among U.S. Adults," researchers investigated the blood sugar-related effects of cannabis use among participants in the National Health and Nutrition Examination Survey from 2005 to 2010. The study showed there was a potential benefit from the use of cannabis.

As more and more states are legalizing the use of medical marijuana, research that centers on the effects of cannabis is starting to become more prevalent. This, of course, is good news for Nuvilex's subsidiary Medical Marijuana Sciences.

Nuvilex knows a little something about areas of this study relating to insulin and blood sugar levels. In a 6-month study, pancreatic islet cells (produce insulin) from pigs were encapsulated using the company's technology and the capsules containing the islet cells were then implanted into live, diabetic rats.

Continue reading this article to learn how marijuana research can benefit Nuvilex's work in Diabetes at

About Stock Market Media Group

Stock Market Media Group, formerly Stock House Group, is a full service Investment Relations firm specializing in Research, Content Development and Awareness. The firm offers a platform for CEOs to tell their story through the media with its Feature Articles, Research Reports, and CEO Interviews. At the same time, the company is building a library of Research on its website for Investors to become better informed on small cap stocks. For more information visit:

Contact Information